Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer
January 6, 2025
Authors:
L. Angelats, L. Paré, C. Rubio-Perez, E. Sanfeliu, A. González, E. Seguí, G. Villacampa, M. Marín-Aguilera, S. Pernas, B. Conte, V. Albarrán-Fernández, O. Martínez-Sáez, Á. Aguirre, P. Galván, A. Fernandez-Martinez, S. Cobo, M. Rey, A. Martínez-Romero, B. Walbaum, F. Schettini, M. Vidal, W. Buckingham, M. Muñoz, B. Adamo, Y. Agrawal, S. Guedan, T. Pascual, J. Agudo,M. Grzelak, N. Borcherding, H. Heyn, A. Vivancos, J. S. Parker, P. Villagrasa, C. M. Perou, A. Prat, F. Brasó-Maristany
Affiliations:
August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Hospital Clinic of Barcelona, University of Barcelona, Reveal Genomics, Vall d’Hebron Institute of Oncology, Institut Catala d’Oncologia (IDIBELL), L’Hospitalet de Llobregat, Institut Català d’Oncologia Medical Oncology, Breast Unit Barcelona, University of North Carolina, SOLTI Cancer Cooperative Group, DanaFarber Cancer Institute, Boston, Harvard Medical School, New York Stem Cell Foundation, Robertson Investigator, Omniscope Inc., Vall d’Hebron Institute of Oncology (VHIO), Cancer Genomics Group, Institute of Oncology (IOB)dHospital Quirónsalud
